首页> 美国卫生研究院文献>PLoS Clinical Trials >Complement-Mediated Virus Infectivity Neutralisation by HLA Antibodies Is Associated with Sterilising Immunity to SIV Challenge in the Macaque Model for HIV/AIDS
【2h】

Complement-Mediated Virus Infectivity Neutralisation by HLA Antibodies Is Associated with Sterilising Immunity to SIV Challenge in the Macaque Model for HIV/AIDS

机译:HLA抗体对补体介导的病毒感染性的中和与针对猕猴的HIV / AIDS模型的SIV挑战的消毒免疫有关。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sterilising immunity is a desired outcome for vaccination against human immunodeficiency virus (HIV) and has been observed in the macaque model using inactivated simian immunodeficiency virus (SIV). This protection was attributed to antibodies specific for cell proteins including human leucocyte antigens (HLA) class I and II incorporated into virions during vaccine and challenge virus preparation. We show here, using HLA bead arrays, that vaccinated macaques protected from virus challenge had higher serum antibody reactivity compared with non-protected animals. Moreover, reactivity was shown to be directed against HLA framework determinants. Previous studies failed to correlate serum antibody mediated virus neutralisation with protection and were confounded by cytotoxic effects. Using a virus entry assay based on TZM-bl cells we now report that, in the presence of complement, serum antibody titres that neutralise virus infectivity were higher in protected animals. We propose that complement-augmented virus neutralisation is a key factor in inducing sterilising immunity and may be difficult to achieve with HIV/SIV Env-based vaccines. Understanding how to overcome the apparent block of inactivated SIV vaccines to elicit anti-envelope protein antibodies that effectively engage the complement system could enable novel anti-HIV antibody vaccines that induce potent, virolytic serological response to be developed.
机译:杀菌免疫是针对人类免疫缺陷病毒(HIV)疫苗接种的理想结果,并且已在使用灭活的猿猴免疫缺陷病毒(SIV)的猕猴模型中观察到。这种保护作用归因于对细胞蛋白具有特异性的抗体,包括在疫苗和攻击病毒制备过程中掺入病毒粒子的人白细胞抗原(HLA)I和II类。我们在这里显示,使用HLA磁珠阵列,与未保护的动物相比,免受病毒攻击的接种猕猴具有更高的血清抗体反应性。此外,反应性被证明是针对HLA框架决定因素。先前的研究未能将血清抗体介导的病毒中和与保护相关联,并被细胞毒性作用所混淆。现在我们使用基于TZM-b1细胞的病毒进入试验报告,在存在补体的情况下,中和病毒感染性的血清抗体滴度在受保护的动物中更高。我们建议补体增强的病毒中和是诱导灭菌免疫力的关键因素,可能很难用基于HIV / SIV Env的疫苗来实现。了解如何克服灭活的SIV疫苗的明显阻滞,以引发有效参与补体系统的抗包膜蛋白抗体,可以使能够诱导有效的,病毒性血清学反应的新型抗HIV抗体疫苗得以开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号